# US 2012/0252723 A1 · Regulating the Amino Acid Pool Used for the Acute-Phase Protein Synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252723 A1
- Document ID: US20120252723A1
- Status: Published application
- Kind: A1
- Application number: 13/391,398
- Filed: 2010-08-23
- Published: 2012-10-04
- Earliest claimed: 2009-08-21
- Assignees: N.V. Nutricia
- Inventors: Klaske van Norren; Johannes Adrianus Cornelis Peters; Mirian Lansink
- Web page: https://patentgrep.com/patent/US20120252723A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/17: Amino acids, peptides or proteins
- A23L 33/175: Amino acids
- A23L 33/18: Peptides; Protein hydrolysates
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention is directed at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition in a subject having an inflammation or an infection, wherein the combination is to be administered enterally.

## Claims

### Claim 1

A combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and wherein the combination forms part of a nutritional composition that has a glycaemic index below 55.

### Claim 2

A combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition in a subject having an inflammation or an infection, wherein the combination is to be administered enterally and wherein the combination forms part of a nutritional composition that has a glycaemic index below 55.

### Claim 3 (depends on 2)

A combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use according to claim 2, wherein the therapeutic or prophylactic treatment of is a treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition for acute-phase protein synthesis.

### Claim 4 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the combination forms part of a nutritional composition that has a glycaemic index below 55.

### Claim 5 (depends on 1)

A combination for use in a treatment according to claim 1, further comprising (v) at least one component selected from the group consisting of phenylalanine, threonine, tryptophan, methionine and lysine.

### Claim 6 (depends on 5)

A combination for use in a treatment according to claim 5, wherein the total relative amount of branched amino acids as a weight percentage of the total amount of leucine, isoleucine, valine, phenylalanine, threonine, tryptophan, methionine and lysine is in the range of 45-75 weight %.

### Claim 7 (depends on 1)

A combination for use in a treatment according to claim 1, comprising a nutritional anti-inflammatory component.

### Claim 8 (depends on 7)

A combination for use in a treatment according to claim 7, wherein the nutritional anti-inflammatory component is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), eicosatetraenoic acid (ESA), docosapentaenoic acid (DPA), glycine, and nutritional components inhibiting COX II activity.

### Claim 9 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the total relative amount of leucine, isoleucine, valine, phenylalanine, threonine, tryptophan, methionine and lysine, relative to the total amount of amino acids in the composition is in the range of 40-80 weight %.

### Claim 10 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the total relative amount of serine, cysteine and arginine, relative to the total amount of essential amino acids in the composition is in the range of 10-40 weight %.

### Claim 11 (depends on 1)

A combination for use in a treatment according to claim 1, wherein said amino acid or said amino acids are provided in at least one of the following forms: as a free amino acid (including its zwitter ionic state); as a salt of free amino acid; as a peptide comprising one or more of the amino acid units; as a protein comprising one or more of the amino acid units, which protein may be intact or partially hydrolysed; cysteine as cystine; as a conjugate of the amino acid with a conjugating compound other than an amino acid, a protein, or a peptide, which conjugate is capable of being split into the free amino acid (or salt thereof), preferably in the gut or stomach or after absorption in the enterocytes or liver.

### Claim 12 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the combination comprises one or more peptides having 8 or more amino acid units, and the total content of said peptides is at least 50 weight %, based on total proteinaceous matter.

### Claim 13 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the inflammation is caused by a chronic infection, a chronic disease, a systemic elevation of metabolites causing inflammation or by increased concentrations of auto-immune complexes.

### Claim 14 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the concentration of an acute phase protein in blood of the subject to be treated is more than 25% above a maximum normal physiological value in healthy individuals or more than 25% below a minimum normal physiological value in healthy individuals.

### Claim 15 (depends on 3)

A combination for use in a treatment according to claim 3, wherein the acute phase protein is selected from the group consisting of haptoglobulin, serum amyloid protein, mannose binding protein, ferritin, ceruloplasmin, serpin, tyransthyretin, transferrin, fibrinogen, pre-albumin and transcortin.

### Claim 16 (depends on 1)

A combination for use in a treatment according to claim 1, wherein the subject to be treated is a cancer patient, an HIV-infected subject, an AIDS patient, a COPD patient, a subject with renal failure, a subject with heart failure, a subject with insulin resistance, a subject having rheumatoid arthritis or osteoarthritis, a subject having pancreatitis, a subject having hepatitis, a subject having inflammatory bowel disease, a subject having Crohn's disease, a subject having an organ graft, a subject recovering from lesions applied to a body during surgery, a critically-ill subject, a terminally ill subject, an intoxicated individual or a subject suffering from an allergy.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

Combination for use according to claim 1, wherein the combination is to be administered orally.

### Claim 19

Nutritional composition comprising 4-9 weight % serine, 0.7-8 weight % of cysteine, 2-4 weight % arginine 8.0-20 weight % leucine, 3-8.0 weight % isoleucine, 3-8.0 weight % valine, 2.5-8.0 weight % phenylalanine, 3-7 weight % threonine, 1.0-3 weight % trypthophan, 1.0-3.0 weight % methionine, 7.5-12 weight % lysine, and 0-10 weight % glycine, all based on total weight of proteinaceous matter, and wherein the nutritional composition has a glycaemic index below 55.

### Claim 20 (depends on 19)

Nutritional composition according to claim 19, comprising at least one additional ingredient selected from the group consisting of digestible carbohydrates, indigestible carbohydrates and other dietary fibres, trace elements, minerals, vitamins, proteinaceous matter other than proteinaceous matter providing said amino acids, lipids, and inhibitors of COX II activity.

### Claim 21 (depends on 20)

Nutritional composition according to claim 20, having a glycaemic index of 5-45.

### Claim 22 (depends on 20)

Nutritional composition according to claim 20, comprising one or more ω-3 polyunsaturated fatty acid(s), the total amount of ω-3 polyunsaturated fatty acid(s), based on total proteinaceous matter, being at least 4 weight %.

### Claim 23 (depends on 19)

The nutritional composition of claim 19 being an enteral food composition.

### Claim 24 (depends on 5)

The combination of claim 5 including phenylalanine, threonine, tryptophan, methionine and lysine.
